Member news Promising Results on Early Alzheimer’s Diagnosis
Promising Results on Early Alzheimer’s Diagnosis
Friday, 14 October 2011 14:07
The collaborative project between Nansen Neuroscience Network members DiaGenic and Pfizer on early blood-based diagnosis of Alzheimer’s shows promising results.
|
Alzheimer’s Disease
Mild Cognitive Impairment
|
The objective of the project is to identify blood-based biomarkers that may be useful in diagnosing and monitoring of Alzheimer’s disease. On October 14, DiaGenic reported in a press release that the preliminary findings are positive. The study consisted of a total of 120 subjects, including healthy elderly controls, patients with mild cognitive impairment and patients with Alzheimer’s.
According to Sam Gandy, Professor of Neurology and Psychiatry and Director of Mount Sinai Alzheimer's Disease Research Center, such a blood-based test that will allow early diagnosis of Alzheimer’s will be critical to achieving the ultimate goal of preventing the onset of dementia.
Photo: Image comparing a healthy brain with that of a patient with Alzheimer’s. The image is from www.topnews.com.
By Johanne Egge Rinholm for Nansen Neuroscience Network
Add this page to your favorite Social Bookmarking websites
Supported by 